Embecta Corp.
NASDAQ:EMBCDrug Manufacturers - Specialty & Generic
+$0.02 today
- Market cap
- $345.06M
- Beta
- 0.81
- P/E (TTM)
- 1.6
- EPS (TTM)
- $1.92
- Dividend yield
- 14.79%
Volume 0.72M
Average 1.95M
EMBC Common Stock Issued
Cash raised by issuing new shares.
Embecta Corp.NASDAQ: EMBC
Common Stock Issued · Q2 FY2026 · quarter ended Mar 2026
Common stock issued outflow grows to $0
Q2 FY2026 common stock issued was $0, compared with $0 a year earlier. Trailing-twelve-month common stock issued was $0.
Context
- Common stock issued amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
- Common stock issued increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly common stock issued holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Cash FlowText generated from reported figures; not investment advice.
Common Stock Issued history
USD · from the cash flow
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Common Stock Issued | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | 0 | — |
| FY2024 | 2024-09-30 | 0 | — |
| FY2023 | 2023-09-30 | 0 | — |
| FY2022 | 2022-09-30 | 0 | — |
| FY2021 | 2021-09-30 | 0 | — |
Common Stock Issued vs competitors
How EMBC compares with its peers on the latest reported figures
- EMBC's LTM Mar 2026 common stock issued of $0 is the 8th largest of the 11 companies compared; the peer median is $2.9M.
- Common stock issued amounts to 0.0% of revenue for EMBC, versus a peer median of 0.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $166.07M | +3268.6% | -47.4% | 253.6% | |
| LTM Mar 2026 | $132.59M | +16.1% | — | 205.5% | |
| LTM Mar 2026 | $85.04M | +266.4% | +96.7% | 169.2% | |
| LTM Jun 2026 | $5.5M | -59.6% | — | 1.2% | |
| LTM Mar 2026 | $3.3M | — | — | 0.4% | |
| LTM Mar 2026 | $2.5M | -77.1% | — | 0.4% | |
| LTM Mar 2026 | $393K | -99.8% | -9.0% | 9.7% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Jun 2026 | $0 | +100.0% | — | 0.0% | |
| LTM Mar 2026 | $0 | -100.0% | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding EMBC) | $2.9M | -21.7% | -9.0% | 0.8% | |
Competitors are the stored peer set for EMBC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Sep 2021 | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 |
|---|---|---|---|---|---|
| Net Income | 415M | 223.6M | 70.4M | 78.3M | 95.4M |
| Depreciation & Amortization | 38M | 31.7M | 32.6M | 36.2M | 40.7M |
| Deferred Income Tax | (2M) | (26.5M) | 14.3M | (70.6M) | 17.6M |
| Stock-Based Compensation | 12.8M | 18.7M | 21.5M | 26.3M | 31.6M |
| Change in Working Capital | (32M) | 92.4M | (80M) | (47.7M) | (23.7M) |
| Accounts Receivables | (32M) | 122.7M | 7M | (174.7M) | 44.2M |
| Inventory | (18M) | (23.4M) | (28.8M) | (16.5M) | (6.1M) |
| Accounts Payables | 30M | 73.3M | 7.9M | 60M | (68.9M) |
| Other Working Capital | (12M) | (80.2M) | (66.1M) | 83.5M | 7.1M |
| Other Non-Cash Items | 24.2M | 72.3M | 8.9M | 13.2M | 30.1M |
| Operating Cash Flow | 456M | 412.2M | 67.7M | 35.7M | 191.7M |
| Capital Expenditures | (39M) | (24M) | (26.5M) | (15.8M) | (9.3M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (39M) | (24M) | (26.5M) | (15.8M) | (9.3M) |
| Debt Repayment | 0 | 1.44B | (10.7M) | (35.9M) | (186M) |
| Common Stock Issued | 0 | 0 | 0 | 0 | 0 |
| Common Stock Repurchased | 0 | 0 | (3.6M) | (3M) | (5.7M) |
| Dividends Paid | 0 | (8.6M) | (34.4M) | (34.5M) | (35M) |
| Other Financing Activities | (417M) | (1.48B) | 0 | 0 | 0 |
| Financing Cash Flow | (417M) | (48M) | (48.7M) | (73.4M) | (226.7M) |
| Effect of Forex Changes | 0 | (9.3M) | 3.1M | 1.2M | (1.3M) |
| Net Change in Cash | 0 | 330.9M | (4.4M) | (52.3M) | (45.6M) |
| Free Cash Flow | 417M | 388.2M | 41.2M | 19.9M | 182.4M |
Embecta Corp.
NASDAQ:EMBC
Intrinsic Alpha fair value
Locked
Current Price
$6.09
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.